Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.

[1]  R. Ozols,et al.  The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.

[2]  W. Carney,et al.  TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients , 2010, BMC Cancer.

[3]  A. Reuss,et al.  Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Ituro Inoue,et al.  Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets , 2010, PloS one.

[5]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[6]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[7]  J. Blaakær,et al.  Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance? , 2009, Acta obstetricia et gynecologica Scandinavica.

[8]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[9]  F. Jänicke,et al.  C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma , 2008, British Journal of Cancer.

[10]  J. Jacobson,et al.  Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival , 2008, British Journal of Cancer.

[11]  R. Ozols,et al.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Tropé,et al.  Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer. , 2006, Gynecologic oncology.

[13]  A. Reuss,et al.  Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. , 2006, Journal of the National Cancer Institute.

[14]  H. Kitchener,et al.  The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[15]  R. Kimmig,et al.  Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Trimble,et al.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  A. Gadducci,et al.  Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Sorbe.  Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma , 2003, International Journal of Gynecologic Cancer.

[19]  T. Bauknecht,et al.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.

[20]  D. Cruickshank,et al.  Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? , 2002, Gynecologic Oncology.

[21]  J. Warwick,et al.  Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. , 1995, British Journal of Cancer.

[22]  J. Berek,et al.  Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  L. Einhorn,et al.  Prognostic factors for favorable outcome in disseminated germ cell tumors. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N Gunduz,et al.  Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. , 1983, Cancer research.

[25]  F. Schabel.  Rationale for adjuvant chemotherapy , 1977, Cancer.

[26]  L Simpson-Herren,et al.  Effects of surgery on the cell kinetics of residual tumor. , 1976, Cancer treatment reports.

[27]  W. Cliby,et al.  Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? , 2007, Gynecologic oncology.